Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9523910.26442/20751753.2020.4.200117Review ArticleNon-commercial insulin delivery closed-loop systemsSorokinDaniil Iu.-LaptevDmitry N.laptevdn@yandex.ruEndocrinology Research Centre15042020224273028122021Copyright © 2020, Consilium Medicum2020Despite present-day development and opportunities of diabetes mellitus (DM) type 1 control achievement of disease compensation requires active participation of the patients and is observed only in 16-35% of patients. To improve effectiveness of DM type 1 control and quality of life of DM 1 patients insulin delivery closed-loop systems are being developed that regulate insulin delivery consistently to glycemia levels. At present time there are no approved commercial systems of this kind. That is why patients’ communities are trying on their own to implement this approach that was named Artificial Pancreas System Do-It-Yourself (APSDIY). APSDIY underwent no clinical trials, were not authorized for use, are developed and operated by patients themselves that requires certain technical skills. The users take full responsibility for the device use. APSDIY consists of three components: insulin pump, continuous glucose monitoring system, and mathematical algorithm. APSDIY operating principle is represented by mathematical analysis of incoming data from continuous glucose monitoring system, prognosing glycemia trend and following changes of insulin dosage for maintaining target glucose level. Results of several non-randomized studies were published that mainly show sufficient effectiveness of APSDIY use with decrease of glycated hemoglobin level, increase of time of glucose target levels maintenance, decrease pf glycemia variability, and quality of life improvement. Although there is no reliable information on its safety. The lack of financing is the main problem in randomized studies conducting. Absence of authorization for use does not allow medical practitioners to initiate treatment using insulin delivery closed-loop systems, but they should inform patients and warn them of the risks of using these systems. Despite existing limitations, the number of APSDIY users is increasing every year. Further research is necessary for APSDIY effectiveness and safety evaluation, and for determination of these systems development and use perspectives. Key words: diabetes mellitus, automated insulin delivery closed-loop system, artificial pancreas system. For citation: Sorokin D.Iu., Laptev D.N. Non-commercial insulin delivery closed-loop systems. Consilium Medicum. 2020; 22 (4): 27-30. DOI: 10.26442/20751753.2020.4.200117diabetes mellitusautomated insulin delivery closed-loop systemartificial pancreas systemсахарный диабетсистемы введения инсулина в замкнутом контуреискусственная поджелудочная железа[Sherr JL, Tauschmann M, Battelino T et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. Pediatric Diabetes 2018; 19 (Suppl. 27): 302-25. DOI: 10.1111/pedi.12731][Лаптев Д.Н., Переверзева С.В., Емельянов А.О., Петеркова В.А. Мониторинг применения помповой инсулинотерапии у детей, подростков и молодых пациентов с сахарным диабетом 1 типа в Российской Федерации. Проблемы эндокринологии. 2018; 64 (2): 85-92. DOI: 10.14341/probl8756][Дедов И.И., Шестакова М.В., Петеркова В.А. и др. Сахарный диабет у детей и подростков по данным Федерального регистра Российской Федерации: динамика основных эпидемиологических характеристик за 20132016 гг. Сахарный диабет. 2017; 20 (6): 392-402. DOI: 10.14341/DM9460][Шестакова М.В., Викулова О.К., Железнякова А.В. и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019; 91 (10): 4-13. DOI: 10.26442/00403660.2019.10.000364][Tauschmann M, Thabit H, Bally L et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018; 392: 1321-9. DOI: 10.1016/S0140-6736(18)31947-0][Brown S, Kovatchev B, Raghinaru D et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. New Engl J Med 2019; 381: 1707-17. DOI: 10.1056/NEJMoa1907863][Jennings P, Hussain S. Do-It-Yourself Artificial Pancreas Systems: A Review of the Emerging Evidence and Insights for Healthcare Professionals. J Diabetes Sci Technol 2019. DOI: 10.1177/1932296819894296][Braune K, O'Donnell S, Cleal B et al. Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Children and Adolescents With Type 1 Diabetes: Online Survey and Analysis of Self-Reported Clinical Outcomes. JMIR Mhealth Uhealth 2019; 7 (7). DOI: 10.2196/14087][Melmer A, Zuger T, Lewis DM et al. Glycemic Control in Individuals with Type 1 Diabetes Using an Open Source Artificial Pancreas System (OpenAPS). Diabetes, Obesity Metab 2019; 21 (10): 2333-7. DOI: 10.1111/dom.13810][Lewis D. History and Perspective on DIY Closed Looping. J Diabetes Sci Technol 2019; 13 (4): 790-3. DOI: 10.1177/1932296818808307][Toffanin C, Kozak M, Sumnik Z et al. In Silico Trials of an Open-Source Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. Diabetes Technol Ther 2020; 22 (2): 112-20. DOI:10.1089/dia.2019.0375][Lewis D. Setting Expectations for Successful Artificial Pancreas/Hybrid Closed Loop/Automated Insulin Delivery Adoption. J Diabetes Sci Technol 2018; 12 (2): 533-4. DOI: 10.1177/1932296817730083][Battelino T, Danne T, Bergenstal R et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42 (8): 1593-603. DOI: 10.2337/dci19-0028][Litchman M, Lewis D, Kelly L, Gee P Twitter analysis of #OpenAPS DIY artificial pancreas technology use suggests improved A1C and quality of life. J Diabetes Sci Technol 2019; 13 (2): 164-70. DOI: 10.1177/1932296818795705][Petruzelkova L, Soupal J, Plasova V et al. Excellent glycemic control maintained by open-source hybrid closed-loop AndroidAPS during and after sustained physical activity. Diabetes Technol Ther 2018; 20 (11): 744-50. DOI: 10.1089/dia.2018.0214][For Clinicians - A General Introduction and Guide to OpenAPS. n.d. https://openaps.readthedocs.io/en/latest/docs/Re-sources/clinician-guide-to-OpenAPS.html][For Clinicians - A General Introduction and Guide to AndroidAPS. n.d. https://androidaps.readthedocs.io/en/latest/EN/Re-sources/clinician-guide-to-AndroidAPS.html]